Advanced Oncotherapy – SCDTL testing commences, marking the completion of a further key milestone in LIGHT system development

Commencement of initial SCDTL testing Completion of further key milestone in the development of the LIGHT System Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the first tests have begun on the Side Coupled Drift Tube Linac, in line with the Company’s expected timetable. The SCDTL modules are […]

Advanced Oncotherapy – Director Dealing & Total Voting Rights

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, has been informed that Michael Sinclair, Executive Chairman of the Company, has yesterday sold 7 million ordinary shares of 1 penny each in the Company at 8.25 pence per Share in order to fund the exercise of warrants over 28.5 million Shares […]

Advanced Oncotherapy – Bloomberg Business – RNCOS – Business Consultancy Services: US Proton Therapy Market Outlook 2020

Bloomberg Business – RNCOS – Business Consultancy Services: US Proton Therapy Market Outlook 2020. M2 Communications In light of an alarmingly rising incidence of cancers and limited treatment options, physicians are being forced to look beyond conventional treatments. In such a scenario, Proton Therapy, the most advanced radiation technique available, is being projected as the […]

Advanced Oncotherapy – Proton radiation zaps US wallets.

Proton radiation zaps US wallets. By Melinda Beck Six new proton-beam centres are set to start delivering state-ofthe-art radiation to cancer patients around the country by year’s end. Ten more are expected by 2018, bringing the US total to 30 Link here for full article

Advanced Oncotherapy – Large increase in pediatric patients treated with proton therapy

From Oncology Nurse Advisor: Results from a new nationwide survey indicate a steady increase in the number of pediatric patients who are being treated with proton radiation therapy for cancerous and noncancerous tumors. The research was presented during the 54th Annual Conference of the Particle Therapy Co-Operative Group (PTCOG). Based on a survey of all […]

Advanced Oncotherapy – CEO, CFO & Non-Exec director purchase shares in the company

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Sanjeev Pandya, Chief Executive Officer, and Nicolas Serandour, Chief Financial Officer, informed the Company on 5 June 2015 that they individually purchased 220,000 ordinary shares of 1 penny each in the Company at 9 pence per Ordinary Share on that […]

Advanced Oncotherapy – Director Dealing

Advanced Oncotherapy announces that Michael Sinclair, Executive Chairman of the Company, had yesterday purchased an option over 30 million ordinary shares of 1 penny each in the Company from Brahma AG at a cost of £300,000. The Option vests immediately, expires two years from today’s date and has an exercise price of 10p per Ordinary Share. […]

Advanced Oncotherapy (AVO) – Final Results for the year ended 31 December 2014

Advanced Oncotherapy (AVO), the developer of next generation proton therapy systems for cancer treatment, announces audited results for the year ended 31 December 2014, a year of significant progress in the development of the Company’s LIGHT system. A number of key milestones in the development of the LIGHT system have also been completed following the […]

International Medical Journal – Apollo to get first proton therapy centre in the region

South Asia’s first proton therapy treatment is coming soon at Apollo Hospitals. Proton therapy will provide Apollo’s team of oncologists another critical tool in the fight against cancer. Proton therapy is an advanced form of radiation therapy that uses beams of high-energy protons rather than traditional X-rays to irradiate a tumour. The protons are precisely […]